Financial News

BRIEF-Aimmune Therapeutics expects artemis to enroll 120-160 patients in Europe

* Aimmune Therapeutics completes global enrollment of phase 3 palisade trial of ar101 for the treatment of peanut allergy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback